| Skart: A skewness-and autoregression-adjusted batch-means procedure for simulation analysis A Tafazzoli, JR Wilson IIE Transactions 43 (2), 110-128, 2010 | 67 | 2010 |
| N-Skart: A nonsequential skewness-and autoregression-adjusted batch-means procedure for simulation analysis A Tafazzoli, NM Steiger, JR Wilson IEEE Transactions on Automatic Control 56 (2), 254-264, 2010 | 43 | 2010 |
| Long-term health outcomes of lecanemab in patients with early Alzheimer’s disease using simulation modeling AA Tahami Monfared, A Tafazzoli, W Ye, A Chavan, Q Zhang Neurology and therapy 11 (2), 863-880, 2022 | 40 | 2022 |
| Cost‐effectiveness of ivabradine for heart failure in the United States AR Kansal, MR Cowie, A Kielhorn, S Krotneva, A Tafazzoli, Y Zheng, ... Journal of the American Heart Association 5 (5), e003221, 2016 | 37 | 2016 |
| Alzheimer's disease Archimedes condition-event simulator: development and validation AR Kansal, A Tafazzoli, KJ Ishak, S Krotneva, ADNI Collaboration Alzheimer's & Dementia: Translational Research & Clinical Interventions 4, 76-88, 2018 | 30 | 2018 |
| The potential economic value of lecanemab in patients with early Alzheimer’s disease using simulation modeling AA Tahami Monfared, A Tafazzoli, A Chavan, W Ye, Q Zhang Neurology and Therapy 11 (3), 1285-1307, 2022 | 29 | 2022 |
| The potential value-based price of a multi-cancer early detection genomic blood test to complement current single cancer screening in the USA A Tafazzoli, SD Ramsey, A Shaul, A Chavan, W Ye, AR Kansal, J Ofman, ... Pharmacoeconomics 40 (11), 1107-1117, 2022 | 28 | 2022 |
| Performance of Skart: A skewness-and autoregression-adjusted batch means procedure for simulation analysis A Tafazzoli, JR Wilson, EK Lada, NM Steiger INFORMS Journal on Computing 23 (2), 297-314, 2011 | 26 | 2011 |
| Evaluation of the cost-effectiveness of drug treatment for Alzheimer disease in a simulation model that includes caregiver and societal factors K Ito, R Chapman, SD Pearson, A Tafazzoli, K Yaffe, JH Gurwitz JAMA network open 4 (10), e2129392-e2129392, 2021 | 22 | 2021 |
| Cost-effectiveness of DTG+ ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States S Peng, A Tafazzoli, E Dorman, L Rosenblatt, A Villasis-Keever, ... Journal of medical economics 18 (10), 763-776, 2015 | 19 | 2015 |
| Performance comparison of MSER-5 and N-Skart on the simulation start-up problem AC Mokashi, JJ Tejada, S Yousefi, A Tafazzoli, T Xu, JR Wilson, ... Proceedings of the 2010 Winter Simulation Conference, 971-982, 2010 | 17 | 2010 |
| Probabilistic cost-effectiveness comparison of screening strategies for colorectal cancer A Tafazzoli, S Roberts, R Klein, R Ness, R Dittus ACM Transactions on Modeling and Computer Simulation (TOMACS) 19 (2), 1-29, 2009 | 17 | 2009 |
| A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction A Tafazzoli, OS Reifsnider, L Bellanca, J Ishak, M Carrasco, P Rakonczai, ... The European Journal of Health Economics 24 (9), 1441-1454, 2023 | 14 | 2023 |
| A comparison of screening methods for colorectal cancer using simulation modeling A Tafazzoli, SD Roberts, RM Ness, RS Dittus Proceedings of the Winter Simulation Conference, 2005., 10 pp., 2005 | 8 | 2005 |
| A simulation model to evaluate the potential impact of disease-modifying treatments on burden of illness in Alzheimer’s disease AA Tahami Monfared, A Tafazzoli, W Ye, A Chavan, KA Deger, Q Zhang Neurology and Therapy 11 (4), 1609-1623, 2022 | 6 | 2022 |
| The economic impact of new therapeutic interventions on Neuropsychiatric Inventory (NPI) symptom scores in patients with Alzheimer disease A Tafazzoli, A Kansal, P Lockwood, C Petrie, A Barsdorf Dementia and Geriatric Cognitive Disorders Extra 8 (1), 158-173, 2018 | 6 | 2018 |
| Cost‐effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross‐comparison challenge RLH Handels, C Green, A Gustavsson, WL Herring, B Winblad, A Wimo, ... Alzheimer's & Dementia 19 (5), 1800-1820, 2023 | 5 | 2023 |
| Cost‐effectiveness of DTG+ ABC/3TC versus EFV/TDF/FTC for first‐line treatment of HIV‐1 in the United States S Peng, A Tafazzoli, E Dorman, L Rosenblatt, A Villasis‐Keever, ... Journal of the International AIDS Society 17, 19605, 2014 | 4 | 2014 |
| Lifetime clinical benefits of lecanemab in early Alzheimer’s disease using simulation modeling AAT Monfared, A Tafazzoli, W Ye, A Chavan, Q Zhang Alzheimer’s Dement 18, e069405, 2022 | 3 | 2022 |
| POSB44 Drivers of Value-Based Price (VBP) for a Multi-Cancer Early Detection (MCED) Test A Tafazzoli, SD Ramsey, A Shaul, A Chavan, W Ye, KC Chung, ... Value in Health 25 (1), S68, 2022 | 2 | 2022 |
